Oxford Biomedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, we have a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb and Immune Design Corp.
Company Growth (employees)
Oxford, GB
Size (employees)
247 (est)+7%
Oxford Biomedica was founded in 1995 and is headquartered in Oxford, GB

Oxford Biomedica Office Locations

Oxford Biomedica has an office in Oxford
Oxford, GB (HQ)
Transport Way
Show all (1)

Oxford Biomedica Financials and Metrics

Oxford Biomedica Financials

Oxford Biomedica's revenue was reported to be £27.8 m in FY, 2016 which is a 75% increase from the previous period.

Revenue (FY, 2016)

27.8 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.9 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(16.6 m)

EBITDA (FY, 2016)

(7.6 m)

EBIT (FY, 2016)

(11.3 m)

Market capitalization (31-Oct-2017)

276.4 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

15.3 m
Oxford Biomedica's current market capitalization is £276.4 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


7.2 m18.4 m19.1 m11.2 m7.7 m7.8 m5.4 m13.6 m15.9 m27.8 m

Revenue growth, %


Cost of goods sold

449 k1.3 m437 k593 k555 k667 k1.1 m4.4 m5.8 m11.8 m

Gross profit

6.8 m17.1 m18.7 m10.6 m7.2 m7.1 m4.2 m9.2 m10.1 m15.9 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


11 m8.1 m6.8 m6.7 m6.8 m9 m2.2 m14.2 m9.4 m15.3 m

Accounts Receivable

91 k106 k88 k1.8 m187 k315 k1.7 m4 m8.5 m4.9 m


680 k1.4 m2.7 m2.2 m

Current Assets

45.4 m31.2 m32.2 m18.2 m18.8 m17.6 m6.9 m22.8 m25.7 m27.4 m
    GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (15.3 m)(10 m)(3.5 m)(10.3 m)(12.6 m)(8.7 m)(11.1 m)(8.7 m)(13 m)(16.6 m)

    Cash From Operating Activities

    6.3 m(16 m)3.3 m(12.8 m)(13 m)(10 m)(11 m)(6 m)(13.1 m)(5.1 m)

    Cash From Financing Activities

    345 k611 k396 k303 k18.6 m10.3 m23.6 m25 m17.5 m

    Net Change in Cash

    2.9 m(2.8 m)(1.3 m)(147 k)185 k2.1 m(6.8 m)12 m(4.8 m)6 m
      GBPY, 2016


      112.5 k

      Financial Leverage

      4.5 x
      Show all financial metrics

      Oxford Biomedica Operating Metrics

      Oxford Biomedica's Clinical Programs was reported to be 114 in FY, 2015
      FY, 2015

      Patents Issued


      Clinical Programs

      Show all operating metrics

      Oxford Biomedica Market Value History

      Oxford Biomedica's employees are reported to be approximately 50% female and 50% male.
      Show all human capital metrics

      Oxford Biomedica's Web-traffic and Trends

      Oxford Biomedica Online and Social Media Presence

      Oxford Biomedica Company Life and Culture

      You may also be interested in